| Species |
Human |
| Protein Construction |
Siglec-15 (Phe20-Thr263)
Accession # Q6ZMC9 |
hFc |
| N-term |
C-term |
|
| Purity |
> 90% as analyzed by SDS-PAGE |
| Endotoxin Level |
< 1 EU/μg of protein by gel clotting method |
| Biological Activity |
Immobilized Anti-Siglec15 at 1.0 μg/ml (100 μl/well) can bind Siglec-15, hFc, Human with a EC50 = 5.184 ng/ml and a linear range of 0.064?200.0 ng/ml when detected by Mouse Anti–Human IgG Fc-HRP. |
| Expression System |
HEK 293 |
| Apparent Molecular Weight |
~54.3 kDa, on SDS-PAGE under reducing conditions. |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH?O or PBS up to 100 μg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
Immobilized Anti Siglec15 at 1 μg/ml (100 μl/well) can bind Siglec15 Fc Chimera, Human with a EC50 = 5.184 ng/ml and a linear range of 0.064?200 ng/ml when detected by Mouse Anti–Human IgG Fc-HRP. Background was subtracted from data points before curve fitting.
| Target Background |
Siglec-15 preferentially recognizes the Neu5Acalpha2-6GalNAcalpha- structure. Siglec-15 associates with the activating adaptor proteins DNAX activation protein (DAP)12 and DAP10 via its lysine residue in the transmembrane domain. Siglec-15 is the second human Siglec identified to have an activating signaling potential; unlike Siglec-14, however, it does not have an inhibitory counterpart. |
| Synonyms |
CD33L3; HsT1361; SIGLEC-15 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
